In the United States, bladder cancer is the sixth most common cancer. When cancer is confined to the tissue lining the inner surface of the bladder and has not invaded the bladder's muscle layer, it is classified as non-muscle-invasive bladder cancer (NMIBC). It represents about 80% of all bladder cancer cases and is associated with a high recurrence rate of approximately 50 to 80% over five years. Johnson & Johnson's INLEXZO and Urogen's ZUSDURI are some of the approved drugs for non-muscle-invasive bladder cancer.
The company we are profiling today is Relmada Therapeutics Inc. (RLMD), which is developing a drug for non-muscle invasive bladder cancer.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.